As previously reported, Wedbush analyst Yun Zhong initiated coverage of Opus Genetics (IRD) with an Outperform rating and $8 price target The October 2024 deal to combine the previous private Opus with Ocuphire “created a unique company with two distinctive approaches and a strong focus on ophthalmology indications,” the analyst tells investors in a research note. The firm sees an over $10B market opportunity for Opus’ gene therapy portfolio. It believes clinical and regulatory updates in in the coming months will serve as “strong catalysts” to drive continued share outperformance.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics initiated with an Outperform at Wedbush
- Opus Genetics’ New Study on Vision Improvement: What Investors Need to Know
- Opus Genetics Advances Genetic Therapy for Rare Eye Conditions
- Opus Genetics Advances Gene Therapy for Retinal Degeneration: A Study Update
- Opus Genetics: Promising Gene Therapy Developments and Strategic Advancements Drive Buy Rating